Clinical Trials Browser

INDUSTRY × Expanded_access × Waldenstrom Macroglobulinemia × Clear all

NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Approved for marketing

LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04052854 2024-10-23

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

No longer available

Waldenstrom Macroglobulinemia, Recurrence